The National Institutes of Health has given a five-year $10 million grant to Biosyn Inc., the University of Pennsylvania, Duke University, TherImmune Research Corp., the Southern Research Institute, and St. George's Hospital Medical School in London to continue jointly developing a microbicide to prevent HIV infection through vaginal or anal sex. Early research on the compound, called Cyanovirin-N, has shown that the microbicide is effective in preventing sexual transmission of the simian immunodeficiency virus in monkeys. The grant will be used for preclinical development and clinical trials to test the compound's safety and effectiveness in preventing HIV transmissions among humans.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














